208 related articles for article (PubMed ID: 16188134)
1. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions].
Li XJ; Pan QJ; Shen GH; Liu XY; Sun YT
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):438-41. PubMed ID: 16188134
[TBL] [Abstract][Full Text] [Related]
2. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears.
Lozano MD; Panizo A; Toledo GR; Sola JJ; Pardo-Mindán J
Cancer; 2001 Feb; 93(1):68-72. PubMed ID: 11241268
[TBL] [Abstract][Full Text] [Related]
4. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
5. Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.
Betta PG; Pavesi M; Pastormerlo M; Tallarida F; Bellingeri D; Bocca R
Pathologica; 1991; 83(1083):99-104. PubMed ID: 1866206
[TBL] [Abstract][Full Text] [Related]
6. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers.
Davidson B; Risberg B; Kristensen G; Kvalheim G; Emilsen E; Bjåmer A; Berner A
Virchows Arch; 1999 Jul; 435(1):43-9. PubMed ID: 10431845
[TBL] [Abstract][Full Text] [Related]
7. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology.
Nagel H; Hemmerlein B; Ruschenburg I; Hüppe K; Droese M
Pathol Res Pract; 1998; 194(11):759-64. PubMed ID: 9842634
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical identification of carcinomas of unknown primary in serous effusions.
Pomjanski N; Grote HJ; Doganay P; Schmiemann V; Buckstegge B; Böcking A
Diagn Cytopathol; 2005 Nov; 33(5):309-15. PubMed ID: 16240395
[TBL] [Abstract][Full Text] [Related]
9. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
10. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
11. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology.
Ko EC; Jhala NC; Shultz JJ; Chhieng DC
Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
Khurram N; Anis T; Yusuf NW
J Coll Physicians Surg Pak; 2019 Jan; 29(1):33-36. PubMed ID: 30630566
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
Ang PP; Tan GC; Karim N; Wong YP
Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
[TBL] [Abstract][Full Text] [Related]
14. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
15. [Cell-block immunocytochemical characterization of effusions. Use of antibody panel: calretinin, Ber-EP4, keratin and CD68].
Lucchi I; Morigi F; Naldi S; Tabarri B; Elegibili E; Giangaspero F
Pathologica; 1999 Dec; 91(6):447-52. PubMed ID: 10783640
[TBL] [Abstract][Full Text] [Related]
16. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
17. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions.
Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J
Cancer Res; 1985 Apr; 45(4):1894-900. PubMed ID: 3884146
[TBL] [Abstract][Full Text] [Related]
18. E-cadherin and calretinin as immunocytochemical markers to differentiate malignant from benign serous effusions.
He DN; Zhu HS; Zhang KH; Jin WJ; Zhu WM; Li N; Li JS
World J Gastroenterol; 2004 Aug; 10(16):2406-8. PubMed ID: 15285029
[TBL] [Abstract][Full Text] [Related]
19. Malignant effusions: from diagnosis to biology.
Davidson B
Diagn Cytopathol; 2004 Oct; 31(4):246-54. PubMed ID: 15452897
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of immunohistochemistry in evaluation of malignant pleural and peritoneal effusions.
Ensani F; Nematizadeh F; Irvanlou G
Pol J Pathol; 2011; 62(2):95-100. PubMed ID: 21866465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
